Role of tyrosine kinase-independent phosphorylation of EGFR with activating mutation in cisplatin-treated lung cancer cells

• Published in: Biochemical and biophysical research communications Vol. 458; no. 4; pp. 856 - 861
• Main Authors: Refaat, Alaa, Aminullah, Zhou, Yue, Kawanishi, Miho, Tomaru, Rika, Abdelhamed, Sherif, Shin, Myoung-Sook, Koizumi, Keiichi, Yokoyama, Satoru, Saiki, Ikuo, Sakurai, Hiroaki
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 20.03.2015
• Subjects: Antineoplastic Agents - pharmacology; Apoptosis; Apoptosis - drug effects; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; Cell Line, Tumor; Cisplatin; Cisplatin - pharmacology; Drug Resistance, Neoplasm; EGFR; Humans; Lung - drug effects; Lung - metabolism; Lung - pathology; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - pathology; MAP Kinase Signaling System - drug effects; MAPK; Mutation; NSCLC; Phosphorylation - drug effects; Receptor, Epidermal Growth Factor - genetics; Receptor, Epidermal Growth Factor - metabolism; NSCLC; MAPK; Cisplatin; EGFR; Apoptosis

Epidermal growth factor receptor (EGFR) mutation is one of the hallmarks of cancer progression and resistance to anticancer therapies, particularly non-small cell lung carcinomas (NSCLCs). In contrast to the canonical EGFR activation in which tyrosine residues are engaged, we have demonstrated that...